A safe, clean, and healthful world is both our birthright and our responsibility.

Ei.Ventures is building a platform around the use of natural medicines and their ability to support the symbiosis of happy humans and a healthy planet.

Our ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic.

We seek to provide a free resource to the individual that will provide critical data for further academic understanding of psychoactive compounds.

As the pace of decriminalization continues to snowball, we watch with interest as the legal backdrop and DEA scheduling status remains on the political agenda. In markets that allow self therapy, we anticipate being able to provide a suite of products.

A Global Problem
An alarming growth rate of mental illness
1 out of 5 people

American adults suffer from a mental illness

25 percent

The increase in the prevalence of anxiety & depression worldwide in the last 2 years

65 percent

The increase in antidepressant prescription rate in the last two decades

1 out of 8 people

People over the age of 12are prescribed antidepressants

In Need of Improvement
An increasing distrust of “standard” care

The percent of US adults that say they have confidence in medical scientists to act in the best interest of the public (that is a 40% decrease in just two years)


Compound Annual Growth Rate (CAGR) of the complementary & alternative medicine market, 2021-2030

Complimentary and alternative medicine market size, 2020-2030, USD billion - Pew Research

Complimentary & alternative medicine market size, 2020-2030, USD billion - Pew Research

Consumers are turning to complementary and alternative medicine (including nutraceuticals and herbal medicine) more than ever. A growing distrust in Western medicine, coupled with a distaste for adverse side effects, has shifted the public’s preferences toward whole-body wellness as a necessity for a happier and healthy life.
Plant-powered therapies, supported by science
Ei.Ventures is on its way to becoming the world’s leading source of therapy powered by nature combined with technology for optimized accessibility. We are building a virtual community and educational platform around the use of functional and psychedelic plant medicines to address the growing mental health crisis.
FDA-Regulated Psychedelic Therapies
Plant-based Wellness Products
AR, VR, and Metaverse for Mental Health
A Psychoactive Medicine Renaissance
Change is occurring
This wave of change is being driven by a community that believes the current scheduling of Psilocybin as a schedule 1 compound, alongside drugs such as Heroin, is fundamentally wrong. Currently, Psilocybin is in Phase 2b Clinical Trials with 'breakthrough status' by the FDA. On track to be federally legal by 2024
Magic Mushrooms are the safest drug according to 2017’s Global Drug Survey
TA survey that analyzed over 120,000 individual data points concluded that magic mushrooms were materially safer than any drug. This measured both self harm and harm to others as monitored by global hospital data. Alcohol was found to be the most harmful, a substance legal in all 50 states.ext
Mental Health Stats
Our approach to wellness creates a "farma" vs. pharma debate. We believe this wellness goes beyond the traditional standard of pharma. We're out to prove through cutting edge research and clinical studies that whole plant botanical medicines can be more impactful than the synthetics prescribed for chronic mental health disorders.
Psilocybin gaining support across the U.S. As over 150 cities and several states consider psilocybin reforms, Ei.Ventures is poised to come to market wherever it is within the letter of the law.
Mental Health Stats
people suffer from depression worldwide
people suffer from PTSD worldwide
people suffer from substance abuse worldwide
1 in 5
American adults suffer from a form of mental illness
of people affected by mass conflicts have PTSD
increase in OUD diagnosis in the U.S. from 2010-2016
The estimated cost of depression to the global economy
Estimated global cost of mental health conditions in 2030 by the World Economic Forum (up from $2.5 trillion in 2010)
people die every day from opioid abuse
Psilocybin Clinical Trial Data
Cancer patients
  • 80% of trial participants at 6-month stage following treatment were showing significantly reduced symptoms of anxiety and depression.
  • 80% endorsing moderately or greater increased well-being/life satisfaction.
  • Estimated that only 33% of depression patients benefit from currently available treatment options.
Smoking Cessation
  • 80% of participants were abstinent in the 6 month follow-up, and 73% were biologically confirmed to have quit smoking (Chantix – best-in-class – currently delivers a 35% quit rate).
  • 12 month follow-up showed 67% remained abstinent. In 2017, an additional follow-up confirmed that 60% remained abstinent.
Post Traumatic Stress Disorder
  • 300 million global sufferers.
  • 76% of MDMA-assisted psychotherapy patients were deemed to be successfully treated 12 months after therapy with similar results being seen with psilocybin.
Brief History of Psilocybin
Phase 1
4000 BCE
Prehistoric inhabitants of Spain create cave murals depicting psychedelic mushrooms
Phase 2
Florentine Codex is published and contains desription of Aztecs using peyote and hallucinogenic mushrooms
Phase 3
Albert Hofman isolates two psycoactive compounds, psilocybin and psilocin, and develops a synthetic version of psilocybin used in current research.
Phase 4
A significant amount of promisiong psilocybin research is conducted in the U.S., including Harvard’s Psilocybin Project.
Phase 5
1970 - Present
So-called “Kitchen Chemists”, in the vein of psychelic chemist Sasha Shulgin, continue to advocate the research and development of psilocybin therapies.
Phase 6
June 1, 1971
U.S. President Richard Nixon calls drug abuse in America “public enemy number one”. Psilocybin is becomes a Schedule 1 drug, deemed to have no medical value and have high potential of abuse.
Phase 7
2006 - Present
Studies involving psilocybin start gaining support in the United States.
David headshot
David Nikzad
CEO and Co-Founder
David is an experienced operator, entrepreneur, and angel investor. David has built and sold multiple companies ranging from tech to nightlife. He is considered an “investor savant” and a backer of the most disruptive entrepreneurs and organizations.
Jason headshot
Jason Hobson
COO and Co-Founder
Jason A. Hobson is a successful attorney, entrepreneur and angel investor. Jason plays an integral part in the operational pieces and procedures - harnessing the next wave of entrepreneurs looking to progress new-age sectors and ideas.
Apr 9, 2024

Ei.Ventures, Inc. (“Ei” or the “Company”) has entered into a non-binding letter of intent dated March 25, 2024 (the “Letter of Intent”) with Orthogonal Global Group Inc. (formerly known as Web3 Ventures Inc.) (“OGG”), a global accelerator and public investment platform currently listed on the Canadian Securities Exchange (CSE: OGG), Frankfurt Stock Exchange (FSE: KZ2) and OTC Pink (OTC Pink: OGGIF), focused on furthering initiatives in the wellness, healthcare, AI, blockchain tokenization, deep-tech and gaming spaces, and Orthogonal Thinker, Inc., an accelerator focused on health, wellness, technology, deep-tech and tokenization (“Thinker”), to seize on the convergence of these cutting-edge industries and technologies, and to give access to these otherwise private opportunities on a senior exchange in the North American public capital markets.

David Nikzad, CEO of Ei states “We believe this is the right opportunity to provide liquidity to our shareholders through a merger or combination with OGG and Thinker, and a path forward to determine which public exchange is best for a combined company, especially after the difficult headwinds the last couple of years experienced by companies engaged in psychedelics, the metaverse and blockchain projects and other cutting-edge healing modalities looking to access the public markets.” Without regulatory relief on a federal level for cutting-edge industries like psychedelics and blockchain/crypto initiatives such as the metaverse, the U.S. public capital markets have been difficult to navigate and access for emerging companies. But with the wider adoption of AI, AR/VR, and crypto-based initiatives and products (e.g., BTC ETFs), the convergence of these industries presents an opportunity to expand Ei’s “play to heal” presence in the metaverse (blockchain/NFTs), to further work on technology platforms to give access to healings, the Company’s products and offerings for integration of psychedelic experiences for most of the world’s population which doesn’t have regular access to medical clinics or trained providers engaged in these healings. Given the combined holdings and focus of both OGG and Thinker, as well as shared values and common ownership and control among the companies, Ei entered into the Letter of Intent to lay-out a framework to move forward towards accessing the public capital markets.

The Letter of Intent anticipates the companies will enter into a definitive agreement with terms and conditions of a merger or business combination on or before September 30, 2024, including, but not limited to approved third-party valuations of Ei and Thinker, any regulatory approvals for the merger or business combination required of OGG, approval by the respective board of directors and to the extent required, by the respective shareholders, and an agreed upon path forward to list on a senior exchange in North America or to remain on the CSE and FSE as a combined company, subject to CSE and FSE regulatory approval, among other conditions.

Until a Definitive Agreement is reached, OGG has not circulated a press release or made any filing with the CSE or FSE regarding the Letter of Intent.